Mercer Global Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Mercer Global Advisors’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,108	Closed	-$262K	–	3710
2026 Q1	$262K	Buy	16,108 +5,581	+53%	+$93.3K	﹤0.01%	2574
2025 Q4	$177K	Buy	+10,527	New	+$177K	﹤0.01%	2600

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Mercer Global Advisors's HQL Position: Q2 2026 in Review

Mercer Global Advisors sold out of abrdn Life Sciences Investors (HQL) in Q2 2026, closing a stake of 16,108 shares — an estimated $262K sold.

Mercer Global Advisors first reported a position in HQL in Q4 2025 and held it in 2 quarters. The position peaked at $262K in Q1 2026. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

Mercer Global Advisors reported no remaining abrdn Life Sciences Investors position as of Q2 2026 after selling out during the quarter.
Mercer Global Advisors sold 16,108 abrdn Life Sciences Investors shares in Q2 2026, an estimated $262K.
Mercer Global Advisors first reported a position in abrdn Life Sciences Investors in Q4 2025 and held it in 2 quarters.
Mercer Global Advisors's abrdn Life Sciences Investors position peaked at $262K in Q1 2026.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.